Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 9/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | HPGD | P15428 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14010813 | 0.84 | — | — | |
| SCHEMBL8402970 | 0.84 | ALDH1A1 (0.51) | ALDH1A1CYP2D6CYP3A4TSHRCYP2C9 | |
| SCHEMBL11406691 | 0.80 | — | — | |
| SCHEMBL944668 | 0.80 | ALDH1A1 (0.53) | ALDH1A1TSHRCYP1A2MAPTHPGD | |
| SCHEMBL2904238 | 0.80 | ALDH1A1 (0.44) | ALDH1A1TSHRMAPTHPGDSMN1; SMN2 | |
| SCHEMBL3552242 | 0.80 | HPGD (0.41) | ALDH1A1CYP3A4HSD17B10HPGDSMN1; SMN2 | |
| SCHEMBL1220310 | 0.78 | KMT2A (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2KMT2A | |
| SCHEMBL13450960 | 0.78 | KMT2A (0.52) | ALDH1A1MAPTHPGDSMN1; SMN2KMT2A | |
| SCHEMBL4257 | 0.78 | AKR1C3 (0.37) | ALDH1A1CYP3A4TSHRHSD17B10HPGD | |
| SCHEMBL508614 | 0.77 | GAA (0.51) | ALDH1A1CYP1A2MAPTSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | claimed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | claimed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | claimed |
| EP-1200433-B1 | C-6 RING-SUBSTITUTED PYRIDO[1,2-a]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-03-22 | — | — | EP | claimed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | claimed |
| EP-1200433-A1 | C-6 RING-SUBSTITUTED PYRIDO 1,2- i a /i ]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2002-05-02 | — | — | EP | claimed |
| US-6358946-B1 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS, SEDATIVES, MUSCLE RELAXANTS, ANTICONVULSANTS, AND HYPNOSIS AGENTS; SLEEP DISORDER TREATMENT | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2002-03-19 | — | — | US | claimed |
| WO-2001009132-A1 | C-6 RING-SUBSTITUTED PYRIDO[1,2-a]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-02-08 | — | — | WO | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | disclosed |
| EP-2017278-B1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVE | MSD KK (JP) | 2016-11-02 | — | — | EP | disclosed |
| EP-2376493-B1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVE | MSD KK (JP) | 2016-10-05 | — | — | EP | disclosed |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD KK (JP) | 2014-10-09 | — | — | US | disclosed |
| US-8791125-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2014-07-29 | — | — | US | disclosed |
| EP-1200433-B1 | C-6 RING-SUBSTITUTED PYRIDO[1,2-a]BENZIMIDAZOLE DERIVATIVES USEFUL IN TREATING CENTRAL NERVOUS SYSTEM DISORDERS | ORTHO MCNEIL PHARM INC (US) | 2006-03-22 | — | — | EP | disclosed |
| US-20060020012-A1 | Pyrazole derivatives | PFIZER INC | 2006-01-26 | — | — | US | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
| EP-1377556-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | Pfizer Limited (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | disclosed |
| WO-2002085860-A1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LIMITED (GB) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | ALDH1A1 320/4885CYP2D6 830/4885CYP3A4 704/4885 |
| US-20060020012-A1 | Pyrazole derivatives | PDCD11, RTF1, REV1 | ALDH1A1 997/4885CYP2D6 229/4885CYP3A4 55/4885 |
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ALDH1A1 385/4885CYP2D6 106/4885CYP3A4 47/4885 |
| US-20140303178-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE1, WEE2, GRK3 | ALDH1A1 755/4885CYP2D6 996/4885CYP3A4 1626/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.